Sino Biopharmaceutical (OTCMKTS:SBMFF) Stock Price Down 1.2% - Time to Sell?

Key Points

• Stock fell 1.2% on Tuesday to last trade at $0.8299 (intraday low $0.7936) as volume spiked to 2,312 shares, an ~8,625% increase from the average daily volume of 27 shares.
• Shares are trading below both the 50-day ($0.85) and 200-day ($0.92) moving averages, suggesting short- and long-term technical weakness.
• Sino Biopharmaceutical is a Hong Kong–incorporated pharmaceutical investment holding company with operations across infusion solutions, small-molecule drugs and biologics, and it reports low leverage (debt-to-equity 0.07) with modest liquidity (current ratio 1.36, quick ratio 1.28).

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report)'s stock price was down 1.2% during trading on Tuesday . The stock traded as low as $0.7936 and last traded at $0.8299. Approximately 2,312 shares traded hands during mid-day trading, an increase of 8,625% from the average daily volume of 27 shares. The stock had previously closed at $0.8399.

Sino Biopharmaceutical Price Performance

The firm's 50-day moving average price is $0.85 and its two-hundred day moving average price is $0.92. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.36 and a quick ratio of 1.28.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited OTCMKTS: SBMFF is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China's domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.

The company's product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.